Bio-Path raises ~$4M in private placement; launches obesity drug program BP1001-A

BIO-PATH HOLDINGS, INC.

Gross proceeds of ~$4.0M from private placement of pre-funded warrants and series A/B warrants at $0.87 per unit; warrants exercisable at $1.00 per share.
Initiated development of BP1001-A for obesity using DNAbilize technology; IND-enabling testing expected to begin in Q4 2024.
Completed enrollment of third dosing cohort (60 mg/m2) of Phase 1/1b trial of BP1002 in refractory/relapsed AML patients.
Cancelled prior June 2024 series A and B warrants (1,809,955 shares each) held by the same investor upon closing of this placement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.